Changes in CD69, CD25 and HLA-DR expressions in peripheral blood T cells in Kawasaki disease.
- Author:
Yi-ying ZHANG
1
;
Xian-mei HUANG
;
Man-li KANG
;
Fang-qi GONG
;
Bai-qin QIAN
Author Information
- Publication Type:Journal Article
- MeSH: Antigens, CD; blood; Antigens, Differentiation, T-Lymphocyte; blood; Aspirin; administration & dosage; therapeutic use; Biomarkers; blood; Child, Preschool; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Flow Cytometry; Glucocorticoids; therapeutic use; HLA-DR Antigens; blood; Humans; Immunoglobulins, Intravenous; therapeutic use; Immunologic Factors; therapeutic use; Infant; Interleukin-2 Receptor alpha Subunit; blood; Lectins, C-Type; blood; Male; Methylprednisolone; therapeutic use; Mucocutaneous Lymph Node Syndrome; blood; diagnosis; drug therapy; immunology; Platelet Aggregation Inhibitors; therapeutic use; Prognosis; T-Lymphocytes; drug effects; immunology; Treatment Outcome
- From: Chinese Journal of Pediatrics 2006;44(5):329-332
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThe study was designed to investigate the changes in CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell in Kawasaki disease (KD).
METHODSThe authors detected CD(69), CD(25) and HLA-DR expressions in peripheral blood T cell by using flow cytometry. The patients who met the diagnostic criteria for KD comprised sixteen boys and fifteen girls (4 - 60 months of age; mean, 26 +/- 18 months). All received intravenous gammaglobulin at a dose of 1 g/(kg.d), for 2 days and oral aspirin at a dose of 30 - 50 mg/(kg.d). In case of persistent fever, a repeated dose of intravenous gammaglobulin or I.V. methylprednisolone at a dose of 20 mg/(kg.d) for three daily doses was attempted. The authors tested blood samples from 17 healthy controls consisting of nine boys and eight girls (3 - 84 months of age; mean, 25 +/- 18 months) and the samples from 31 patients.
RESULTSThe percentage of peripheral blood CD(3)(+) T lymphocyte was (54.4 +/- 9.0)% in acute stage of KD and (65.0 +/- 7.0)% in healthy controls. There was a significant difference between the two groups (P < 0.001). The values of CD(69)(+) [(11.2 +/- 12.6)%, vs. (0.6 +/- 0.4)%], CD(25)(+) [(9.2 +/- 3.5)% vs. (3.9 +/- 1.8)%] and HLA-DR(+) [(8.3 +/- 5.0)% vs. (4.3 +/- 2.3)%] in KD patients were markedly increased compared to those of the healthy controls. After intravenous gammaglobulin treatment, the percentage of CD(3)(+)CD(69)(+) and CD(3)(+)CD(25)(+) significantly decreased [CD(3)(+)CD(69)(+): (14.0 +/- 13.0)% vs. (1.6 +/- 1.2)%, P < 0.05; CD(3)(+)CD(25)(+): (7.8 +/- 4.1)% vs. (2.0 +/- 0.6)%, P < 0.01]. However, the CD(3)(+) T lymphocytes increased [(50.8 +/- 5.0)% vs. (64.9 +/- 5.5)%, P < 0.01]. There was no significant difference in expression of CD(3)(+) T lymphocyte cell activating markers between coronary artery disease group and normal coronary artery group in KD cases (P > 0.05).
CONCLUSIONCD(3)(+) T cell activation in the early and middle stages is involved in the mechanism responsible for cardiovascular injury.